{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 462260534
| IUPAC_name = ''N''-(3-Methyl-1,1-dioxido-4-thiomorpholinyl)-1-(5-nitro-2-furyl)methanimine
| image = Nifurtimox.svg
| width = 250px
| chirality = [[Racemic mixture]]

<!--Clinical data-->
| tradename = Lampit<ref name=Drugs1995/>
| synonyms  = Bayer 2502<ref name=Drugs1995/>
| Drugs.com = {{drugs.com|CONS|nifurtimox}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category = Undetermined
| legal_status = ℞ only
| routes_of_administration = By mouth

<!--Pharmacokinetic data-->
| bioavailability = Low
| metabolism = [[Liver]] ([[Cytochrome P450 oxidase|CYP]] involved)
| elimination_half-life = 2.95 ± 1.19 hours
| excretion = [[Kidney]], very low

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 23256-30-6
| ATC_prefix = P01
| ATC_suffix = CC01
| ATC_supplemental = {{ATCvet|P51|AC01}}
| PubChem = 31772
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 29464
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = M84I3K7C2O
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00833
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 290960

<!--Chemical data-->
| C=10 | H=13 | N=3 | O=5 | S=1 
| molecular_weight = 287.293 g/mol
| smiles = O=S2(=O)CC(N(N=Cc1oc([N+]([O-])=O)cc1)CC2)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C10H13N3O5S/c1-8-7-19(16,17)5-4-12(8)11-6-9-2-3-10(18-9)13(14)15/h2-3,6,8H,4-5,7H2,1H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = ARFHIAQFJWUCFH-UHFFFAOYSA-N
| melting_point     = 180
| melting_high      = 182
}}

<!-- Definition and medical uses -->
'''Nifurtimox''' is a medication used to treat [[Chagas disease]] and [[African trypanosomiasis|sleeping sickness]].<ref name=Drugs1995/><ref name=WHO19th/> For sleeping sickness it is used together with [[eflornithine]].<ref name=WHO19th/> In Chagas disease it is a second line option to [[benznidazole]].<ref name=Bern2007/> It is given by mouth.<ref name=Drugs1995/>

<!-- Side effects and mechanism -->
Common side effects include abdominal pain, headache, nausea, and weight loss.<ref name=Drugs1995/> There are concerns from animal studies that it may increase the risk of [[cancer]] but these concerns have not be found in human trials.<ref name=Bern2007/> Nifurtimox is not recommended in [[pregnancy]] or in those with significant kidney or [[liver problems]].<ref name=Bern2007/> It is a type of [[nitrofuran]].<ref name=Bern2007/>

<!-- Society and culture -->
Nifurtimox came into medication use in 1965.<ref name=Bern2007>{{Cite journal|last=Bern|first=Caryn|last2=Montgomery|first2=Susan P.|last3=Herwaldt|first3=Barbara L.|last4=Rassi|first4=Anis|last5=Marin-Neto|first5=Jose Antonio|last6=Dantas|first6=Roberto O.|last7=Maguire|first7=James H.|last8=Acquatella|first8=Harry|last9=Morillo|first9=Carlos|date=2007-11-14|title=Evaluation and Treatment of Chagas Disease in the United States |url=http://jamanetwork.com/journals/jama/fullarticle/209410|journal=JAMA|volume=298|issue=18|doi=10.1001/jama.298.18.2171|issn=0098-7484|pmid=18000201|pages=2171–81}}</ref> It is on the [[World Health Organization's List of Essential Medicines]], the most effective and safe medicines needed in a [[health system]].<ref name=WHO19th>{{cite web|title=WHO Model List of Essential Medicines (19th List)|url=http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1|work=World Health Organization|accessdate=8 December 2016|date=April 2015|deadurl=no|archiveurl=https://web.archive.org/web/20161213052708/http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1|archivedate=13 December 2016|df=}}</ref> It is not available commercially in Canada or the United States.<ref name=Drugs1995>{{cite web|title=Nifurtimox (Systemic)|url=https://www.drugs.com/cons/nifurtimox.html|date=1995|website=Drugs.com|accessdate=3 December 2016|deadurl=no|archiveurl=https://web.archive.org/web/20161220042503/https://www.drugs.com/cons/nifurtimox.html|archivedate=20 December 2016|df=}}</ref> In the United States the medication can be gotten from the [[Center for Disease Control]].<ref name=CDC2013Tx>{{Cite web|url=https://www.cdc.gov/parasites/chagas/health_professionals/tx.html|title=CDC - Chagas Disease - Resources for Health Professionals - Antiparasitic Treatment|last=Prevention|first=CDC - Centers for Disease Control and|website=www.cdc.gov|accessdate=2016-11-09|deadurl=no|archiveurl=https://web.archive.org/web/20161106123343/http://www.cdc.gov/parasites/chagas/health_professionals/tx.html|archivedate=2016-11-06|df=}}</ref> It cost about 20 USD for a course of treatment as of 2013.<ref>{{cite book|last1=Dumas|first1=Michel|last2=Bouteille|first2=Bernard|last3=Buguet|first3=Alain|title=Progress in Human African Trypanosomiasis, Sleeping Sickness|date=2013|publisher=Springer Science & Business Media|isbn=9782817808574|page=268|url=https://books.google.com/books?id=zL_zBwAAQBAJ&pg=PA268|language=en|deadurl=no|archiveurl=https://web.archive.org/web/20161220044017/https://books.google.com/books?id=zL_zBwAAQBAJ&pg=PA268|archivedate=2016-12-20|df=}}</ref> In regions of the world where the disease is common nifurtimox is provided for free by the [[World Health Organization]].<ref name=WHO2016>{{cite web|title=Trypanosomiasis, human African (sleeping sickness)|url=http://www.who.int/mediacentre/factsheets/fs259/en/|website=World Health Organization|accessdate=7 December 2016|date=February 2016|deadurl=no|archiveurl=https://web.archive.org/web/20161204153318/http://www.who.int/mediacentre/factsheets/fs259/en/|archivedate=4 December 2016|df=}}</ref>

==Medical uses==
Nifurtimox has been used to treat [[Chagas disease]], when it is given for 30 to 60 days.<ref>{{cite journal |vauthors=Coura JR, de Castro SL | title=A critical review of Chagas disease chemotherapy | journal=Mem Inst Oswaldo Cruz | year=2002 | volume=97 | pages=3–24 | doi=10.1590/S0074-02762002000100001 | pmid=11992141 | issue=1}}</ref><ref name=":0">{{Cite web|url=https://www.drugs.com/mmx/nifurtimox.html|title=Nifurtimox Drug Information, Professional|website=www.drugs.com|accessdate=2016-11-09|deadurl=no|archiveurl=https://web.archive.org/web/20161108140805/https://www.drugs.com/mmx/nifurtimox.html|archivedate=2016-11-08|df=}}</ref> However, long term use of Nifurtimox does increase chances of adverse events like [[Gastrointestinal tract|gastrointestinal]] and [[Neurology|neurological]] side effects.<ref name=":0" /><ref name=":1">{{Cite journal|last=Jackson|first=Yves|last2=Alirol|first2=Emilie|last3=Getaz|first3=Laurent|last4=Wolff|first4=Hans|last5=Combescure|first5=Christophe|last6=Chappuis|first6=François|date=2010-11-15|title=Tolerance and Safety of Nifurtimox in Patients with Chronic Chagas Disease|url=http://cid.oxfordjournals.org/content/51/10/e69|journal=Clinical Infectious Diseases|language=en|volume=51|issue=10|pages=e69–e75|doi=10.1086/656917|issn=1058-4838|pmid=20932171}}</ref> Due to the low tolerance and completion rate of Nifurtimox, [[benznidazole]] is now being more considered for those who have Chagas disease and require long term treatment.<ref name=Bern2007/><ref name=":1" />

Nifurtimox has also been used to treat [[African trypanosomiasis]] (sleeping sickness), and is active in the second stage of the disease ([[central nervous system]] involvement). When nifurtimox is given on its own, about half of all patients will relapse,<ref>{{cite journal |vauthors=Pepin J, Milord F, Mpia B, etal | title=An open clinical trial of nifurtimox for arseno-resistant ''T. b. gambiense'' sleeping sickness in central Zaire | journal=Trans R Soc Trop Med Hyg | year=1989 | volume=83 | pages=514–7 | doi=10.1016/0035-9203(89)90270-8 | pmid=2694491 | issue=4}}</ref> but the combination of [[melarsoprol]] with nifurtimox appears to be efficacious.<ref>{{cite journal |vauthors=Bisser S, N'Siesi FX, Lejon V | title=Equivalence Trial of Melarsoprol and Nifurtimox Monotherapy and Combination Therapy for the Treatment of Second-Stage Trypanosoma brucei gambiense Sleeping Sickness | journal=J Infect Dis | year=2007 | volume=195 | pages=322–329 | doi=10.1086/510534 | pmid=17205469 | issue=3|display-authors=etal}}</ref> Trials are awaited comparing [[melarsoprol]]/nifurtimox against melarsoprol alone for African sleeping sickness.<ref>{{cite journal | author=Pepin J | title=Combination Therapy for Sleeping Sickness: A Wake-Up Call | journal=J Infect Dis | year=2007 | volume=195 | pages=311–13 | doi=10.1086/510540 | pmid=17205466 | issue=3}}</ref>

Combination therapy with [[eflornithine]] and nifurtimox is safer and easier than treatment with eflornithine alone, and appears to be equally or more effective. It has been recommended as first-line treatment for second-stage African trypanosomiasis.<ref>{{cite journal |vauthors=Priotto G, Kasparian S, Mutombo W, etal |title=Nifurtimox-eflornithine combination therapy for second-stage African ''Trypanosoma brucei gambiense'' trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial |journal=Lancet |volume=374 |issue=9683 |pages=56–64 |date=July 2009 |pmid=19559476 |doi=10.1016/S0140-6736(09)61117-X}}</ref>

=== Pregnancy and breastfeeding ===
Use of nifurtimox should be avoided in pregnant women due to limited use.<ref name=Bern2007 /><ref name=":0" /><ref>{{Cite book|url=https://books.google.com/books?id=L2NzAwAAQBAJ&pg=PA124&lpg=PA124&dq=Nifurtimox+pregnancy&source=bl&ots=XzIcQyHD_0&sig=_2ucLo3S4ng_MtnTsjGknCbCXtM&hl=en&sa=X&ved=0ahUKEwiR486g5ZfQAhVkslQKHUVFCysQ6AEIVTAI#v=onepage&q=Nifurtimox%20pregnancy&f=false|title=Drugs During Pregnancy and Lactation: Treatment Options and Risk Assessment|last=Schaefer|first=Christof|last2=Peters|first2=Paul W. J.|last3=Miller|first3=Richard K.|date=2014-09-17|publisher=Academic Press|isbn=9780124079014|language=en|deadurl=no|archiveurl=https://web.archive.org/web/20170908221306/https://books.google.com/books?id=L2NzAwAAQBAJ&pg=PA124&lpg=PA124&dq=Nifurtimox+pregnancy&source=bl&ots=XzIcQyHD_0&sig=_2ucLo3S4ng_MtnTsjGknCbCXtM&hl=en&sa=X&ved=0ahUKEwiR486g5ZfQAhVkslQKHUVFCysQ6AEIVTAI#v=onepage&q=Nifurtimox%20pregnancy&f=false|archivedate=2017-09-08|df=}}</ref> There is limited data shown that nifurtimox doses up to 15&nbsp;mg/kg daily can cause adverse effects in breastfed infants.<ref name=":6">{{Cite web|url=https://www.drugs.com/breastfeeding/nifurtimox.html|title=Nifurtimox use while Breastfeeding {{!}} Drugs.com|website=www.drugs.com|accessdate=2016-11-07|deadurl=no|archiveurl=https://web.archive.org/web/20161108140741/https://www.drugs.com/breastfeeding/nifurtimox.html|archivedate=2016-11-08|df=}}</ref> Other authors do not consider breastfeeding a contraindication during nifurtimox use.<ref name=":6" />

==Side effects==
Side effects occur following chronic administration, particularly in elderly people. 
Major toxicities include immediate hypersensitivity such as [[anaphylaxis]] and delayed hypersensitivity reaction involving [[Jaundice|icterus]] and [[dermatitis]]. Central nervous system disturbances and peripheral neuropathy may also occur.<ref name=":0" />

Most common side effects<ref name=CDC2013Tx/><ref name=":0" /><ref name=":5">{{Cite journal|last=Forsyth|first=Colin J.|last2=Hernandez|first2=Salvador|last3=Olmedo|first3=Wilman|last4=Abuhamidah|first4=Adieb|last5=Traina|first5=Mahmoud I.|last6=Sanchez|first6=Daniel R.|last7=Soverow|first7=Jonathan|last8=Meymandi|first8=Sheba K.|date=2016-10-15|title=Safety Profile of Nifurtimox for Treatment of Chagas Disease in the United States|journal=Clinical Infectious Diseases|volume=63|issue=8|pages=1056–1062|doi=10.1093/cid/ciw477|issn=1537-6591|pmc=5036918|pmid=27432838}}</ref><ref>{{Cite journal|last=Castro|first=José A.|last2=de Mecca|first2=Maria Montalto|last3=Bartel|first3=Laura C.|date=2006-08-01|title=Toxic side effects of drugs used to treat Chagas' disease (American trypanosomiasis)|journal=Human & Experimental Toxicology|volume=25|issue=8|pages=471–479|issn=0960-3271|pmid=16937919|doi=10.1191/0960327106het653oa}}</ref><ref name=":3">{{Cite journal|last=Estani|first=Sergio Sosa|last2=Segura|first2=Elsa Leonor|date=1999-09-01|title=Treatment of Trypanosoma cruzi infection in the undetermined phase. Experience and current guidelines of treatment in Argentina|url=http://www.scielo.br/scielo.php?script=sci_abstract&pid=S0074-02761999000700070&lng=en&nrm=iso&tlng=en|journal=Memórias do Instituto Oswaldo Cruz|volume=94|pages=363–365|doi=10.1590/S0074-02761999000700070|issn=0074-0276|deadurl=no|archiveurl=https://web.archive.org/web/20101220072916/http://www.scielo.br/scielo.php?script=sci_abstract|archivedate=2010-12-20|df=}}</ref>
* anorexia
* weight loss
* nausea
* vomiting
* headache
* dizziness
* amnesia
Less common effects<ref name="CDC2013Tx" /><ref name=":0" /><ref name=":5" /><ref name=":3" />
* rash
* depression
* anxiety
* confusion
* fever
* sore throat
* chills
* seizures 
* impotence
* tremors
* muscle weakness
* numbness of hands or feet

=== Contraindications ===
Nifurtimox is contraindicated in people with severe liver or kidney disease, as well as people with a background of neurological or psychiatric disorders.<ref name=Bern2007/><ref name="CDC2013Tx" /><ref>{{Cite web|url=http://www.who.int/mediacentre/factsheets/fs340/en/|title=Chagas disease|website=World Health Organization|language=en-GB|accessdate=2016-11-08|deadurl=no|archiveurl=https://web.archive.org/web/20140227181940/http://www.who.int/mediacentre/factsheets/fs340/en/|archivedate=2014-02-27|df=}}</ref>

== Mechanism of action ==
Nifurtimox forms a nitro-anion radical metabolite that reacts with nucleic acids of the parasite causing significant break down of DNA.<ref name=":0" /> Its mechanism is similar to that proposed for the antibacterial action of [[nitrofuran]] agents. Nifurtimox undergoes reduction and creates oxygen radicals such as [[superoxide]]. These radicals are toxic to ''T. cruzi''. Mammalian cells are protected by presence of [[catalase]], [[glutathione]], [[peroxidase]]s, and [[superoxide dismutase]]. Accumulation of hydrogen peroxide to cytotoxic levels results in parasite death.<ref name=":0" />

==Manufacturing and availability==
Nifurtimox is sold as Lampit by Bayer. It was previously known as Bayer 2502.

Nifurtimox is only licensed for use in [[Argentina]] and [[Germany]],{{Citation needed|date=November 2010}} where it is sold as 120-mg tablets. It is not commercially available in the United States, but can be distributed to qualifying healthcare professionals by the Centers for Disease Control and Prevention Drug Service.<ref name="CDC2013Tx" /><ref name=":0" /><ref>{{Cite web|url=https://www.cdc.gov/laboratory/drugservice/formulary.html|title=Our Formulary &#124; Infectious Diseases Laboratories &#124; CDC|website=www.cdc.gov|accessdate=2016-11-08|deadurl=no|archiveurl=https://web.archive.org/web/20161216173833/https://www.cdc.gov/laboratory/drugservice/formulary.html|archivedate=2016-12-16|df=}}</ref>

==Research==
Nifurtimox is in a phase-II clinical trial for the treatment of pediatric [[neuroblastoma]] and [[medulloblastoma]].<ref>{{ClinicalTrialsGov|NCT00601003}}. Retrieved on July 10, 2009.</ref>

==References==
{{reflist|2}}

{{Excavata antiparasitics}}

[[Category:Antiprotozoal agents]]
[[Category:Thiomorpholines]]
[[Category:Nitrofurans]]
[[Category:Sulfones]]
[[Category:Hydrazones]]
[[Category:World Health Organization essential medicines]]
[[Category:RTT]]